niraparib has been researched along with Genital-Neoplasms--Female* in 1 studies
1 review(s) available for niraparib and Genital-Neoplasms--Female
| Article | Year |
|---|---|
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in. JGOG2052 is a single-arm, open-label, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of niraparib monotherapy for a recurrent or persistent rare fraction of gynecologic malignancies with. Japan Primary Registries Network (JPRN) Identifier: jRCT2031210264. Topics: Clinical Trials, Phase II as Topic; Female; Genital Neoplasms, Female; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2022 |